Physician profile
Roselyn A Wills
NPI 1427138940
$1,035.18
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $366 · 2021: $80.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $384.25 | 2019-2021 | |
| Abbvie INC. | $160.91 | 2019-2020 | |
| Amgen INC. | $71.14 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $63.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $46.95 | 2019 | |
| Allergan, INC. | $45.43 | 2019-2020 | |
| Amarin Pharma, INC. | $40.45 | 2019-2020 | |
| Sanofi Pasteur INC. | $34.73 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $34.24 | 2019-2020 | |
| Astellas Pharma US INC | $32.32 | 2019-2020 | |
| Pfizer INC. | $27.91 | 2019 | |
| Abbott Laboratories | $20.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.55 | 2019 | |
| Merck Sharp & Dohme LLC | $15.13 | 2019 | |
| Endo Pharmaceuticals INC. | $14.92 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $13.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roselyn Wills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.